Chamberlain College of Nursing | NR 546 Psychopharmacology for the Psychiatric-Mental
Health Nurse Practitioner
NR 546 Psychopharmacology for the Psychiatric-
Mental Health Nurse Practitioner Midterm
Examination 2026/2027 | Verified Questions
Chamberlain College of Nursing | NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse
Practitioner | University-Level Advanced Practice Nursing Students
100 Verified Questions | 4 Core Domains | Academic Year 2026/2027
Prepared by
Chamberlain College of Nursing | NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse
Practitioner
Midterm Comprehensive Examination Actual Exam | Academic Year 2026/2027
NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Examination 2026/2027
| Verified Questions
,Introduction
This examination contains 100 original Verified Questions organized into four core domains that follow
the official blueprint of the Chamberlain College of Nursing NR 546 Psychopharmacology for the
Psychiatric-Mental Health Nurse Practitioner course: Domain 1, Psychopharmacologic Principles and
Neurobiology, with 25 questions; Domain 2, Psychotropic Medications for Mood and Anxiety Disorders,
with 25 questions; Domain 3, Psychotropic Medications for Psychotic and Cognitive Disorders, with 25
questions; and Domain 4, Special Populations and Psychopharmacological Management, with 25
questions. Every question includes four choices, the correct response, and a rationale that explains the
clinical reasoning.
All content in this document is original and has been written to reinforce the official Chamberlain College
of Nursing NR 546 course objectives for the Midterm Comprehensive Examination, supporting actual
exam readiness and clinical proficiency for University-Level advanced nursing students in the 2026/2027
academic year. The questions and rationales follow the foundational psychiatric pharmacology textbook
methodology of the NR 546 course materials and standard psychopharmacology references, and they
align with current evidence-based psychiatric care standards and mental health treatment guidelines. A
full answer key and a per-domain score tracker are provided at the end so that each domain can be
checked and used to focus further study.
Actual Questions
Domain 1: Psychopharmacologic Principles and Neurobiology
Question 1. According to the classic monoamine hypothesis, what is the proposed
neurochemical basis of major depressive disorder?
A. A deficit of serotonin, norepinephrine, or dopamine signaling in key brain circuits
B. An excess of dopamine at mesolimbic receptors
C. A deficiency of gamma-aminobutyric acid only
D. An excess of acetylcholine at cortical synapse sites
Correct Answer: A
Rationale: The monoamine hypothesis, historically derived from the observation that reserpine depleted
monoamines and induced depression while tricyclics and MAO inhibitors elevated them, proposes that
depression is associated with reduced serotonin, norepinephrine, and dopamine activity in limbic and
prefrontal circuits. It is a foundational concept in the NR 546 course materials and Stahl's
psychopharmacology framework, and it explains why agents that increase monoamine transmission
are effective, even though modern models emphasize receptor adaptation and neuroplasticity.
Question 2. At which receptor do benzodiazepines act to produce anxiolytic and sedative
effects?
A. The GABA-B receptor, where they increase potassium conductance
B. The NMDA receptor, where they block glutamate binding
C. The 5-HT1A receptor, where they act as partial agonists
D. The GABA-A receptor, where they increase the frequency of chloride channel opening
Correct Answer: D
Rationale: Benzodiazepines bind the benzodiazepine site on the GABA-A receptor complex and enhance
the effect of endogenous GABA, increasing chloride channel opening frequency and hyperpolarizing
neurons, with distinct receptor subunit composition underlying anxiolytic, sedative, anticonvulsant, and
amnestic properties. Their major limitations are tolerance, dependence, and withdrawal risk. This
GABAergic mechanism is a core element of the NR 546 curriculum on anxiolytic pharmacology.
Question 3. Which dopamine pathway is most closely associated with the positive
symptoms of schizophrenia and with antipsychotic drug action?
A. The nigrostriatal pathway, which controls fine motor movement
B. The tuberoinfundibular pathway, which regulates prolactin release
C. The mesolimbic pathway, where D2 receptor blockade reduces psychotic symptoms
D. The mesocortical pathway, which supports executive function and cognition
NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Examination 2026/2027
| Verified Questions
, Correct Answer: C
Rationale: The dopamine hypothesis of schizophrenia holds that excess dopamine activity in the
mesolimbic pathway contributes to positive symptoms such as hallucinations and delusions, which is
why D2 antagonism there is the basis of antipsychotic efficacy. Blockade in the nigrostriatal pathway
causes extrapyramidal symptoms, tuberoinfundibular blockade raises prolactin, and mesocortical
hypodopaminergia contributes to negative and cognitive symptoms. Mapping these pathways is
standard content in the NR 546 course materials.
Question 4. Which receptor blockade in the nigrostriatal dopamine pathway explains
extrapyramidal side effects of typical antipsychotics?
A. 5-HT2A receptor blockade, which raises nigrostriatal dopamine
B. D2 receptor blockade, especially with high-potency agents such as haloperidol
C. H1 receptor blockade in the basal ganglia
D. Alpha-1 blockade at nigrostriatal autoreceptors
Correct Answer: B
Rationale: Typical antipsychotics produce extrapyramidal symptoms because their D2 blockade in the
nigrostriatal pathway mimics dopamine depletion in the basal ganglia; risk is dose-related and greatest
with high-potency agents such as haloperidol. Second-generation agents with 5-HT2A antagonism and
lower D2 affinity produce fewer such effects, and their 5-HT2A blockade increases striatal dopamine
release, which is one mechanistic explanation for a lower EPS burden. This receptor-clinical correlation
is central to NR 546 content.
Question 5. What is the principal mechanism of action of selective serotonin reuptake
inhibitors?
A. Direct stimulation of postsynaptic 5-HT2 receptors
B. Inhibition of monoamine oxidase A and B
C. Blockade of presynaptic alpha-2 autoreceptors
D. Blockade of the serotonin transporter, increasing serotonin in the synaptic cleft
Correct Answer: D
Rationale: SSRIs block the serotonin reuptake pump, increasing synaptic serotonin within hours, while
therapeutic benefit emerges over weeks, illustrating that transporter blockade alone is not the whole
mechanism. Quantitative receptor occupancy, downregulation of somatodendritic 5-HT1A
autoreceptors, and downstream neuroplastic changes are thought to underlie the delayed onset of
benefit. This distinction between immediate synaptic effect and delayed clinical response is a key
teaching point in the NR 546 course materials.
Question 6. Which medication's primary mechanism is selective blockade of the
norepinephrine transporter?
A. Buspirone
B. Atomoxetine
C. Escitalopram
D. Quetiapine
Correct Answer: B
Rationale: Atomoxetine is a selective norepinephrine reuptake inhibitor approved for attention-deficit
hyperactivity disorder, increasing norepinephrine and, in the prefrontal cortex, dopamine through the
norepinephrine transporter, which is why it is effective without being a stimulant. Escitalopram is a
serotonin reuptake inhibitor, buspirone is a 5-HT1A partial agonist, and quetiapine is a dopamine and
serotonin antagonist. Matching drug class to transporter mechanism is a core NR 546 learning
objective.
Question 7. Which dietary substance interaction is a danger of monoamine oxidase
inhibitor therapy?
A. Tryptophan-rich foods that lower serotonin synthesis
B. Caffeine containing beverages that deplete monoamines
C. Tyramine-rich foods in combination with MAO-A inhibition can trigger a hypertensive crisis
D. Iron-rich foods that chelate the enzyme
NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Examination 2026/2027
| Verified Questions
Health Nurse Practitioner
NR 546 Psychopharmacology for the Psychiatric-
Mental Health Nurse Practitioner Midterm
Examination 2026/2027 | Verified Questions
Chamberlain College of Nursing | NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse
Practitioner | University-Level Advanced Practice Nursing Students
100 Verified Questions | 4 Core Domains | Academic Year 2026/2027
Prepared by
Chamberlain College of Nursing | NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse
Practitioner
Midterm Comprehensive Examination Actual Exam | Academic Year 2026/2027
NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Examination 2026/2027
| Verified Questions
,Introduction
This examination contains 100 original Verified Questions organized into four core domains that follow
the official blueprint of the Chamberlain College of Nursing NR 546 Psychopharmacology for the
Psychiatric-Mental Health Nurse Practitioner course: Domain 1, Psychopharmacologic Principles and
Neurobiology, with 25 questions; Domain 2, Psychotropic Medications for Mood and Anxiety Disorders,
with 25 questions; Domain 3, Psychotropic Medications for Psychotic and Cognitive Disorders, with 25
questions; and Domain 4, Special Populations and Psychopharmacological Management, with 25
questions. Every question includes four choices, the correct response, and a rationale that explains the
clinical reasoning.
All content in this document is original and has been written to reinforce the official Chamberlain College
of Nursing NR 546 course objectives for the Midterm Comprehensive Examination, supporting actual
exam readiness and clinical proficiency for University-Level advanced nursing students in the 2026/2027
academic year. The questions and rationales follow the foundational psychiatric pharmacology textbook
methodology of the NR 546 course materials and standard psychopharmacology references, and they
align with current evidence-based psychiatric care standards and mental health treatment guidelines. A
full answer key and a per-domain score tracker are provided at the end so that each domain can be
checked and used to focus further study.
Actual Questions
Domain 1: Psychopharmacologic Principles and Neurobiology
Question 1. According to the classic monoamine hypothesis, what is the proposed
neurochemical basis of major depressive disorder?
A. A deficit of serotonin, norepinephrine, or dopamine signaling in key brain circuits
B. An excess of dopamine at mesolimbic receptors
C. A deficiency of gamma-aminobutyric acid only
D. An excess of acetylcholine at cortical synapse sites
Correct Answer: A
Rationale: The monoamine hypothesis, historically derived from the observation that reserpine depleted
monoamines and induced depression while tricyclics and MAO inhibitors elevated them, proposes that
depression is associated with reduced serotonin, norepinephrine, and dopamine activity in limbic and
prefrontal circuits. It is a foundational concept in the NR 546 course materials and Stahl's
psychopharmacology framework, and it explains why agents that increase monoamine transmission
are effective, even though modern models emphasize receptor adaptation and neuroplasticity.
Question 2. At which receptor do benzodiazepines act to produce anxiolytic and sedative
effects?
A. The GABA-B receptor, where they increase potassium conductance
B. The NMDA receptor, where they block glutamate binding
C. The 5-HT1A receptor, where they act as partial agonists
D. The GABA-A receptor, where they increase the frequency of chloride channel opening
Correct Answer: D
Rationale: Benzodiazepines bind the benzodiazepine site on the GABA-A receptor complex and enhance
the effect of endogenous GABA, increasing chloride channel opening frequency and hyperpolarizing
neurons, with distinct receptor subunit composition underlying anxiolytic, sedative, anticonvulsant, and
amnestic properties. Their major limitations are tolerance, dependence, and withdrawal risk. This
GABAergic mechanism is a core element of the NR 546 curriculum on anxiolytic pharmacology.
Question 3. Which dopamine pathway is most closely associated with the positive
symptoms of schizophrenia and with antipsychotic drug action?
A. The nigrostriatal pathway, which controls fine motor movement
B. The tuberoinfundibular pathway, which regulates prolactin release
C. The mesolimbic pathway, where D2 receptor blockade reduces psychotic symptoms
D. The mesocortical pathway, which supports executive function and cognition
NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Examination 2026/2027
| Verified Questions
, Correct Answer: C
Rationale: The dopamine hypothesis of schizophrenia holds that excess dopamine activity in the
mesolimbic pathway contributes to positive symptoms such as hallucinations and delusions, which is
why D2 antagonism there is the basis of antipsychotic efficacy. Blockade in the nigrostriatal pathway
causes extrapyramidal symptoms, tuberoinfundibular blockade raises prolactin, and mesocortical
hypodopaminergia contributes to negative and cognitive symptoms. Mapping these pathways is
standard content in the NR 546 course materials.
Question 4. Which receptor blockade in the nigrostriatal dopamine pathway explains
extrapyramidal side effects of typical antipsychotics?
A. 5-HT2A receptor blockade, which raises nigrostriatal dopamine
B. D2 receptor blockade, especially with high-potency agents such as haloperidol
C. H1 receptor blockade in the basal ganglia
D. Alpha-1 blockade at nigrostriatal autoreceptors
Correct Answer: B
Rationale: Typical antipsychotics produce extrapyramidal symptoms because their D2 blockade in the
nigrostriatal pathway mimics dopamine depletion in the basal ganglia; risk is dose-related and greatest
with high-potency agents such as haloperidol. Second-generation agents with 5-HT2A antagonism and
lower D2 affinity produce fewer such effects, and their 5-HT2A blockade increases striatal dopamine
release, which is one mechanistic explanation for a lower EPS burden. This receptor-clinical correlation
is central to NR 546 content.
Question 5. What is the principal mechanism of action of selective serotonin reuptake
inhibitors?
A. Direct stimulation of postsynaptic 5-HT2 receptors
B. Inhibition of monoamine oxidase A and B
C. Blockade of presynaptic alpha-2 autoreceptors
D. Blockade of the serotonin transporter, increasing serotonin in the synaptic cleft
Correct Answer: D
Rationale: SSRIs block the serotonin reuptake pump, increasing synaptic serotonin within hours, while
therapeutic benefit emerges over weeks, illustrating that transporter blockade alone is not the whole
mechanism. Quantitative receptor occupancy, downregulation of somatodendritic 5-HT1A
autoreceptors, and downstream neuroplastic changes are thought to underlie the delayed onset of
benefit. This distinction between immediate synaptic effect and delayed clinical response is a key
teaching point in the NR 546 course materials.
Question 6. Which medication's primary mechanism is selective blockade of the
norepinephrine transporter?
A. Buspirone
B. Atomoxetine
C. Escitalopram
D. Quetiapine
Correct Answer: B
Rationale: Atomoxetine is a selective norepinephrine reuptake inhibitor approved for attention-deficit
hyperactivity disorder, increasing norepinephrine and, in the prefrontal cortex, dopamine through the
norepinephrine transporter, which is why it is effective without being a stimulant. Escitalopram is a
serotonin reuptake inhibitor, buspirone is a 5-HT1A partial agonist, and quetiapine is a dopamine and
serotonin antagonist. Matching drug class to transporter mechanism is a core NR 546 learning
objective.
Question 7. Which dietary substance interaction is a danger of monoamine oxidase
inhibitor therapy?
A. Tryptophan-rich foods that lower serotonin synthesis
B. Caffeine containing beverages that deplete monoamines
C. Tyramine-rich foods in combination with MAO-A inhibition can trigger a hypertensive crisis
D. Iron-rich foods that chelate the enzyme
NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Examination 2026/2027
| Verified Questions
